Shares of clinical-stage immuno-oncology company Affimed N.V. (AFMD) are up more than 20% Friday morning after the company announced positive initial data from the Phase 1 study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed's innate cell engager (ICE), AFM13 in solid tumors.
Affimed said all four patients experienced significant disease reduction, with two complete responses and two partial responses, with an objective response rate of 100%.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.